Figure 4 | British Journal of Cancer

Figure 4

From: Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer

Figure 4

Apoptotic CTCs are less effectively captured by CEK or CPK methods. SKBR3 (HER2+ breast cancer) or HCC827 (EGFR mutant NSCLC) cells treated with vehicle or tyrosine kinase inhibitor (SKBR3: 1 μM lapatinib and HCC827; 1 μM gefitinib) for 24 h and processed with (A) CEK method. (B) CPK method or (C) smeared directly on slide without processing. Plots depict percentage of cells (±1 s.d.) staining for Ki67 (open bars, proliferation marker) or TUNEL (closed bars, apoptosis marker) by immunohistochemistry. (D) Percentage of CPK-processed CTCs from patients with NSCLC staining positive for KI67 and TUNEL. (E) Comparison of KI67 expression in CTCs recovered by CEK or CPK methods.

Back to article page